Type 1 Diabetes Mellitus Clinical Trial
Official title:
Comparison of Two Carbohydrate Intake Strategies to Improve Glucose Control During Exercise in Adolescents and Adults With Type 1 Diabetes
NCT number | NCT03214107 |
Other study ID # | SNACK-1 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 3, 2017 |
Est. completion date | August 2, 2019 |
Verified date | June 2020 |
Source | Institut de Recherches Cliniques de Montreal |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To prevent hypoglycemia during prolonged exercise (>30 minutes), additional carbohydrate intake is frequently required. Carbohydrate intake required will vary with insulin regimens, timing and type of exercise as well as starting blood glucose level. In addition to the amount of carbohydrate ingested, the timing of carbohydrate intake could also have an impact on glucose control during exercise. Therefore, the objective of this study will be to compare the efficacy of two snacking strategies to maintain glucose levels in the target range during an exercise period in adolescents and adults with type 1 diabetes: 1) a snack containing ~0.5g of carbohydrates per kilogram of body weight - rounded to the nearest 5g - given 5 minutes before exercise; 2) a snack containing ~0.5g of carbohydrates per kilogram of body weight - rounded to the nearest 5g - distributed this way: ~40% given 5 minutes before exercise, ~30% after 20 minutes of exercise and the last ~30% after 40 minutes of exercise.
Status | Completed |
Enrollment | 37 |
Est. completion date | August 2, 2019 |
Est. primary completion date | August 2, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years and older |
Eligibility |
Inclusion Criteria: 1. Males and females = 14 years of old. 2. Clinical diagnosis of type 1 diabetes for at least one year. 3. Last (less than 3 months) HbA1c = 10%. 4. Patients using multiple daily injections with basal-bolus insulin regimen. Exclusion Criteria: 1. Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator. 2. Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 3. Abnormal blood panel and/or anemia. 4. Ongoing pregnancy. 5. Severe hypoglycemic episode within two weeks of screening. 6. Other serious medical illness likely to interfere with study participation or with the ability to complete the exercise periods by the judgment of the investigator (e.g. orthopedic limitation). 7. Treatment with CSII (Continuous Subcutaneous Insulin Infusion) "insulin pump therapy". |
Country | Name | City | State |
---|---|---|---|
Canada | Institut de recherches cliniques de Montréal | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Institut de Recherches Cliniques de Montreal |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of time of capillary glucose levels spent between 4-10 mmol/L | This time frame corresponds to the exercise period and the 1 hour following it | This outcome will be measured over 120 minutes | |
Secondary | Percentage of time of sensor glucose levels spent between 4-10 mmol/L | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | ||
Secondary | Percentage of time of glucose levels spent below 4 mmol/L | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | ||
Secondary | Decrease in glucose levels | Difference between glucose level at the start of the exercise and the lowest glucose level from the start of the exercise until 1) the end of the exercise and 2) 1 hour after the end of the exercise. | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | |
Secondary | Increase in glucose level | Difference between glucose level at the start of the exercise and the highest glucose level from the start of the exercise until 1) the end of the exercise and 2) 1 hour after the end of the exercise. | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | |
Secondary | Number of participants with an exercise-induced hypoglycemia below 4 mmol/L | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | ||
Secondary | Number of participants with an exercise-induced hypoglycemia below 3.5 mmol/L | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | ||
Secondary | Number of participants requiring an oral treatment for hypoglycemia | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | ||
Secondary | Total number of hypoglycemia episodes requiring treatment | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | ||
Secondary | Percentage of time of glucose levels spent above 10 mmol/L | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | ||
Secondary | Mean time (minutes) to the first hypoglycemic event | This outcome will be measured for the exercise period only (60 minutes) | ||
Secondary | Mean glucose levels | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | ||
Secondary | Standard deviation of glucose levels | This outcome will be measured for the exercise period only (60 minutes) and for the exercise period and the hour following the exercise (120 minutes) | ||
Secondary | Percentage of time of glucose levels between 4 and 10 mmol/L | Dinner time will be up to the patient. | From the end of the exercise period to dinner time. | |
Secondary | Percentage of time of glucose levels between 4 and 10 mmol/L | From the end of the exercise period to midnight (7.5 hours) | ||
Secondary | Percentage of time of glucose levels between 4 and 10 mmol/L | From midnight to 6:00 next morning (6 hours) | ||
Secondary | Percentage of time of glucose levels between 4 and 10 mmol/L | From the end of the exercise period to 6:00 next morning (13.5 hours) | ||
Secondary | Percentage of time of glucose levels spent below 4 mmol/L | Dinner time will be up to the patient. | From the end of the exercise period to dinner time | |
Secondary | Percentage of time of glucose levels spent below 4 mmol/L | From the end of the exercise period to midnight (7.5 hours) | ||
Secondary | Percentage of time of glucose levels spent below 4 mmol/L | From midnight to 6:00 next morning (6 hours) | ||
Secondary | Percentage of time of glucose levels spent below 4 mmol/L | From the end of the exercise period to 6:00 next morning (13.5 hours) | ||
Secondary | Percentage of time of glucose levels spent above 10 mmol/L | Dinner time will be up to the patient | From the end of the exercise period to dinner time | |
Secondary | Percentage of time of glucose levels spent above 10 mmol/L | From the end of the exercise period to midnight (7.5 hours) | ||
Secondary | Percentage of time of glucose levels spent above 10 mmol/L | From midnight to 6:00 next morning (6 hours) | ||
Secondary | Percentage of time of glucose levels spent above 10 mmol/L | From the end of the exercise period to 6:00 next morning (13.5 hours) | ||
Secondary | Number of participants requiring treatment for hypoglycemia | Dinner time will be up to the patient | From the end of the exercise period to dinner time | |
Secondary | Number of participants requiring treatment for hypoglycemia | From the end of the exercise period to midnight (7.5 hours) | ||
Secondary | Number of participants requiring treatment for hypoglycemia | From midnight to 6:00 next morning (6 hours) | ||
Secondary | Number of participants requiring treatment for hypoglycemia | From the end of the exercise period to 6:00 next morning (13.5 hours) | ||
Secondary | Number of hypoglycemic episodes requiring treatment | Dinner time will be up to the patient | From the end of the exercise period to dinner time | |
Secondary | Number of hypoglycemic episodes requiring treatment | From the end of the exercise period to midnight (7.5 hours) | ||
Secondary | Number of hypoglycemic episodes requiring treatment | From midnight to 6:00 next morning (6 hours) | ||
Secondary | Number of hypoglycemic episodes requiring treatment | From the end of the exercise period to 6:00 next morning (13.5 hours) | ||
Secondary | Mean glucose levels | Dinner time will be up to the patient | From the end of the exercise period to dinner time | |
Secondary | Mean glucose levels | From the end of the exercise period to midnight (7.5 hours) | ||
Secondary | Mean glucose levels | From midnight to 6:00 next morning (6 hours) | ||
Secondary | Mean glucose levels | From the end of the exercise period to 6:00 next morning (13.5 hours) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 | |
Completed |
NCT02558491 -
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
|
N/A | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 |